Celcuity (NASDAQ:CELC - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued to investors on Tuesday, Zacks reports.
CELC has been the subject of a number of other reports. Citizens Jmp reissued a "market outperform" rating and issued a $177.00 price target on shares of Celcuity in a research report on Monday, August 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celcuity in a research note on Tuesday, September 1st. Needham & Company LLC reduced their target price on shares of Celcuity from $140.00 to $134.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Wall Street Zen upgraded shares of Celcuity from a "strong sell" rating to a "sell" rating in a report on Saturday, November 14th. Finally, Stifel Nicolaus dropped their price target on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Celcuity presently has a consensus rating of "Moderate Buy" and an average target price of $151.79.
Read Our Latest Report on CELC
Celcuity Stock Down 4.2%
Shares of CELC opened at $55.60 on Tuesday. Celcuity has a 52 week low of $53.54 and a 52 week high of $151.02. The stock has a 50 day moving average price of $70.38 and a two-hundred day moving average price of $97.42. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 14.59.
Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, beating analysts' consensus estimates of ($1.51) by $0.30. On average, analysts forecast that Celcuity will post -5.08 earnings per share for the current year.
Institutional Trading of Celcuity
A number of hedge funds have recently bought and sold shares of the business. Soleus Capital Management L.P. bought a new position in Celcuity in the 3rd quarter valued at $133,813,000. Assenagon Asset Management S.A. increased its position in shares of Celcuity by 685.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company's stock valued at $117,579,000 after purchasing an additional 1,290,466 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Celcuity during the 2nd quarter worth $153,928,000. Wellington Management Group LLP raised its stake in shares of Celcuity by 111.4% during the 2nd quarter. Wellington Management Group LLP now owns 906,595 shares of the company's stock worth $94,848,000 after purchasing an additional 477,643 shares during the period. Finally, Apis Capital Advisors LLC raised its stake in shares of Celcuity by 5.4% during the 3rd quarter. Apis Capital Advisors LLC now owns 567,200 shares of the company's stock worth $45,104,000 after purchasing an additional 29,200 shares during the period. 63.33% of the stock is currently owned by institutional investors.
Key Headlines Impacting Celcuity
These are some of the CELC headlines that stood out recently:
- Positive Sentiment: HC Wainwright kept its Buy rating and $150 price target. It also modestly improved its Q3 2027 EPS estimate to a loss of $0.73 per share from a loss of $0.80. MarketBeat coverage
- Negative Sentiment: The larger revisions were downward: HC Wainwright now expects a 2026 loss of $5.23 per share, versus $4.84 previously, and a 2027 loss of $3.87, versus $3.10. It also raised projected losses for Q4 2026 and each of the first, second, and fourth quarters of 2027.
- Negative Sentiment: Longer-term earnings expectations were cut substantially: the 2028 forecast shifted from $0.92 profit to a $1.38 loss; 2029 profit was reduced from $3.78 to $1.32 per share; and 2030 profit was lowered from $7.21 to $4.00. These changes suggest a slower path to profitability and are the clearest potential headwind for CELC. MarketBeat coverage
About Celcuity
(
Get Free Report)
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.